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Abstract In the mouse fibrosarcoma cell line L929sA, tumor
necrosis factor (TNF) stimulates activation of the stress-
responsive p38 mitogen-activated protein kinase (MAPK), as
well as the classical p42 and p44 MAPK. TNF signaling can be
mediated by p55 or p75 TNF receptors. Here, we demonstrate
that TNF-R55 is sufficient to activate p42/p44 MAPK and p38
MAPK. Moreover, by expressing different membrane-bound or
purely cytoplasmic truncations of TNF-R55, we show that the
intracellular death domain of TNF-R55 is the crucial domain
involved. The cytoplasmic membrane-proximal region of TNF-
R55, known to induce neutral sphingomyelinase activation, is not
required for activation of p38 MAPK or p42/p44 MAPK.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Tumor necrosis factor (TNF) is a pleiotropic cytokine me-
diating activities as diverse as cell proliferation, cell di¡eren-
tiation and cell death. It is also an important mediator of
in£ammation and cellular immune responses, and is involved
in the pathology of many diseases [1]. TNF e¡ects are initi-
ated by binding of the cytokine to speci¢c cell surface recep-
tors, namely p55 (TNF-R55) and p75 (TNF-R75), which are
present on most cell types [2]. Although the receptors are
deprived of any intrinsic kinase activity, TNF clearly activates
several kinases, such as the classical protein kinases (PK)C K
[3] and PKA [4], but also ceramide-activated PK (CAPK) [5],
PKC j [6] and L-casein kinase [7]. Another family of TNF-
stimulated kinases is the MAPK family. The three MAPK
subfamilies, namely c-jun N-terminal kinase (JNK), p38
MAPK and p42/p44 MAPK, become activated by phospho-
rylation on threonine and tyrosine residues by upstream dual-
speci¢ty kinases. The stress-responsive JNK and p38 MAPK
are potently activated in response to cellular stress and in£am-
matory cytokines, such as TNF and interleukin (IL)-1, in al-
most every cell type [8^11]. p42/p44 MAPK are mainly acti-
vated by growth factors via a Ras-Raf-1-dependent pathway.
However, this subdivision of MAPK-activating stimuli is cer-
tainly not absolute, since several reports clearly demonstrated
the activation of p42/p44 MAPK by TNF in endothelial cells,
macrophages, primary ¢broblasts, etc. [12^16]. Furthermore,
in the murine ¢brosarcoma cell line L929sA, we have previ-
ously shown that TNF also activates classical MAPK [17] and
p38 MAPK [10]. Moreover, making use of speci¢c MAPK
inhibitors, we demonstrated that both classes of MAPK are
involved in TNF-induced IL-6 and GM-CSF gene induction
[10,18].
A major breakthrough in elucidating TNF signaling came
from the identi¢cation of several cytosolic proteins that, di-
rectly or indirectly, associate with the intracellular domains of
the TNF receptors [19]. Two distinct domains have been char-
acterized for TNF-R55. The N-terminal, membrane-proximal
region (MPR) plays an important role in signaling to the
neutral (N) sphingomyelinase pathway [20], as well as in in-
ducing nitric oxide synthase [21] and in the TNF-induced
translocation of mitochondria [22]. N-Sphingomyelinase acti-
vation can be linked to MAPK activation, via ceramide-acti-
vated protein kinase (CAPK), which initiates the Ras-Raf-1-
signaling cascade [23,24]. However, in the case of TNF-in-
duced N-sphingomyelinase, subsequent activation of Raf-1
kinase activity is still controversial and probably cell type-
speci¢c [15,20,25]. No clear link between TNF-induced acti-
vation of Raf-1 and p42/p44 MAPK has been demonstrated
so far.
The C-terminal, 80 amino acids long death domain (DD) of
TNF-R55 mediates induction of cell death, activation of the
transcription factor NF-UB and IL-6 gene transcription
[21,26]. Following receptor oligomerization, TNF-R55-DD in-
teracts with a TNF-R55-associating DD protein (TRADD).
In turn, TRADD recruits an apoptosis-inducing signaling
complex FADD/FLICE and/or RIP, on the one hand, and
an NF-UB-activating complex TRAF2/NIK and/or RIP on
the other hand [19]. Some of these conclusions were drawn
from overexpression studies with dominant-negative TRAF2
mutants, capable of inhibiting NF-UB-driven reporter gene
constructs. However, experiments with TRAF2 knockout
mice recently revealed that TNF can still induce NF-UB trans-
location to the nucleus in the absence of TRAF2 [27,28]; this
tempers the unique role of TRAF2 in TNF-induced NF-UB
release and subsequent transcriptional activity. Overexpres-
sion assays have also demonstrated that TRAF2 is necessary
for activation of JNK induced by TNF-R55 [29] and TNF-
R75 [11]. This phenomenon was indeed con¢rmed in cells
derived from TRAF2 knockout mice. In addition, TNF-in-
duced activation of p38 MAPK can be blocked by domi-
nant-negative TRAF2, which also points to a possible role
for TRAF2 in p38 MAPK activation [29,30]. However, for
the activation of both p42/p44 MAPK and JNK by TNF
another DD-containing protein was recently described,
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namely MAPK-activating DD (MADD) [31]. Clearly, the ex-
act role of TRAF2 and/or MADD in activating these kinases
is still not fully understood.
We here now demonstrate unambiguously, by stable expres-
sion of physiological amounts of human (h) TNF-R55, that
hTNF-R55 alone is su⁄cient to activate both p42/p44 MAPK
and p38 MAPK in L929sA cells. Various mutants revealed
that these activations require a structurally active DD, and
do not involve N-sphingomyelinase activations. This clearly
demonstrates that TRAF2 and/or MADD, and not the N-
sphingomyelinase-Ras-Raf-1 pathway, are concerned.
2. Materials and methods
2.1. Cell lines and cell culture
TNF-sensitive murine ¢brosarcoma L929sA cells [32] and all stable
cell clones derived thereof were cultured as previously described [26].
2.2. Cytokines and antisera
Puri¢ed Escherichia coli-derived murine TNF was produced in our
laboratory and had a speci¢c biological activity of 1.3U108 IU/mg as
determined in a TNF cytolysis assay; it contained 6 4 ng endotoxin/
mg protein. Recombinant human interferon (IFN)-K (A/D), which is
also active on mouse cells, was a generous gift from Dr. C. Weiss-
mann (University of Zuºrich, Switzerland) and had a speci¢c activity
of 7.9U107 U/mg as determined on murine cells in an L929/vesicular
stomatitis virus assay. htr1 is an agonistic mouse monoclonal IgM
antibody directed against the extracellular domain of hTNF-R55
and was generously provided by Dr. M. Brockhaus (F. Ho¡mann-
La Roche, Basel, Switzerland [33]). R32WS86T is a hTNF-R55-spe-
ci¢c mutein [34]. PD98059, a speci¢c inhibitor of p42/p44 MAPK, was
supplied as powder (Alexis Corporation, Nottingham, UK) and was
dissolved in DMSO.
The phospho-speci¢c p38 (Thr-180/Tyr-182) and p42/p44 (Thr-202/
Tyr-204) MAPK polyclonal rabbit antibodies detect only the dual
phosphorylated form of MAPK. Polyclonal rabbit IgG antibodies
which detect total MAPK levels, independently of the phosphoryla-
tion state of the protein, were used as controls; they were purchased
from New England Biolabs (Beverly, MA, USA) as part of a kit,
which also includes anti-rabbit IgG coupled to horseradish peroxi-
dase, used as second antibody for Western blotting.
2.3. Plasmids and generation of stable cell lines
Generation of stable cell lines from the parental L929sA cell line by
transfection of di¡erent expression plasmids was previously described
[22,26]. The Leu-351CAla mutation in hTNF-R55-DD was created
with a Transformer Site-directed Mutagenesis kit (Clontech Labora-
tories, Palo Alto, CA, USA). The mutator oligonucleotide 5P-
GGTCGCTCGCCCCTAGGCGCCGCAC-3P was used to introduce
the L351A mutation and to remove the EspI restriction site. Mutated
sequences were screened by restriction digest analysis with EspI. After
sequencing, the cDNA of one correct clone was used to construct
pMxCATR55i-L351A, an IFN-K-inducible eukaryotic expression vec-
tor for mutated CAT-R55i at position 351. The stable cell line
L929sA-CAT-R55i-L351A was tested for CAT-R55i-L351A expres-
sion in a radioactive CAT assay [26] and for cytotoxicity after pro-
duction of CAT-R55i-L351A protein.
2.4. p38 MAPK activation assay
All stable cell clones were seeded at 3.5U105 cells/well in 6-well
plates. After 24 h, cells were triggered with 100 ng/ml htr1, 1000
IU/ml IFN-K or 2000 IU/ml TNF. At the end of the incubation
period, cells were washed in PBS. Cell extracts were essentially pre-
pared as described in the protocol of a PhosphoPlus p38 MAPK
antibody kit (New England Biolabs). One ¢fth of the total cell lysate
(20 Wl) was separated by 12% SDS-PAGE and blotted onto a nitro-
cellulose membrane. Western blot analysis was performed to detect
either phosphorylated or, as a control for equal loading, non-phos-
phorylated p38 MAPK.
2.5. p42/p44 MAPK activation assay
Stable cell clones were seeded at 5U105 cells/well in 6-well plates.
After 24 h, the growth medium was replaced with DMEM, supple-
mented with 0.1% newborn calf serum for 48 h to starve the cells.
Subsequently, inductions were carried out in the starved medium.
Western analysis was essentially carried out with a PhosphoPlus
p42/p44 MAPK antibody kit (New England Biolabs), according to
the manufacturer’s instructions.
3. Results
3.1. TNF-R55 constructs and their characterization
in L929sA cells
Fig. 1A gives an overview of the various receptor constructs
used in the present study. hR55wt contains the full-length
wild-type hTNF-R55 cDNA, driven by an SV40 early pro-
moter. In the construct hR55vMPR, the region corresponding
to the membrane-proximal amino acids 203^304 has been re-
moved, leaving mainly the C-terminal-coding part of hTNF-
R55, including the DD, as the intracellular receptor cDNA.
Several cell clones, stably transfected with these constructs,
could be selectively killed, upon treatment with the hTNF-
R55-speci¢c monoclonal agonistic antibody htr1 (data not
shown). From these, two independent clones, called L929sA-
hR55wt and L929sA-hR55vMPR, expressing full-length
hTNF-R55 and the MPR-deleted mutant, respectively, were
retained for further characterization of TNF-R55 and/or DD-
mediated signaling events. Both cell lines were reported to
express physiological relevant levels of hTNF receptors and
to induce cell death upon triggering with htr1 [22].
We also constructed a fusion protein between chloramphen-
icol acetyltransferase (CAT) and the intracellular domain of
the hTNF-R55 (CAT-R55i) [26]. CAT is a bacterial protein,
which spontaneously trimerizes to give the biologically active
form of the enzyme. By linking the cytoplasmic part of
hTNF-R55 to the C-terminal end of CAT, placed under the
control of the IFN-K-inducible Mx promoter [26], we can
generate a cytoplasmic, structural equivalent of the activated
trimerized intracellular part of hTNF-R55. Induced expres-
sion of this CAT-R55i fusion protein in L929sA cells was
shown to elicit an e⁄cient TNF response, i.e. cytotoxicity,
NF-UB activation and IL-6 induction [26]. The CAT-R55i-
L351A construct, containing the Leu-351CAla mutation,
i.e. the TNF-R55 equivalent of the lpr mutation in the Fas
antigen, shown to abolish TNF-induced signaling to cytotox-
icity, NF-UB activation and gene expression [21], was also
stably transfected to L929sA cells. Although expression of
the protein could clearly be demonstrated upon triggering of
the transfected cells with IFN-K (Fig. 1B), no cytotoxicity
could be generated (data not shown). In the construct CAT-
linkDD, only the coding portion of TNF-R55-DD was fused,
over a £exible linker, to CAT cDNA. This construct is again
fully active in signaling to cell killing, NF-UB activation and
IL-6 expression [26].
3.2. p38 MAPK activation is mediated by the TNF-R55
death domain
Activation of p38 MAPK by TNF, shown to be a very
rapid and transient event, is achieved by dual phosphorylation
of the protein on threonine and tyrosine. This phosphoryla-
tion can be demonstrated by the use of speci¢c antibodies
recognizing only the phosphorylated, activated form of the
protein. All the constructions described above were used to
analyse the involvement of TNF-R55 and/or its DD in acti-
vation of the p38 MAPK. hR55WT- or hR55vMPR-express-
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ing cells were treated with TNF or htr1 for di¡erent time
periods. Western blot analysis with phospho-speci¢c p38
MAPK antibody demonstrates that phosphorylation of p38
MAPK can be observed already 5 min after treatment with
TNF (Fig. 2A). Exclusive triggering of full-length hTNF-R55
with htr1 also resulted in the activation of p38 MAPK after
15 min of treatment (Fig. 2A). Clearly, triggering of the
hTNF-R55 alone is su⁄cient to activate p38 MAPK. When
the cells expressing hR55vMPR were incubated with htr1,
activation of p38 MAPK could still be achieved after 15
min of triggering (Fig. 2A). Treatment of parental L929sA
cells with htr1 did not result in activation of p38 MAPK
(data not shown). From these results we can conclude that
in L929sA cells hTNF-R55 activates p38 MAPK through its
DD. Recently, it was shown that a novel region of 11 amino
acids at positions 309^319 in hTNF-R55, called NLD (for N-
sphingomyelinase-linked domain), is necessary and su⁄cient
for activating N-sphingomyelinase [35]. As the deletion var-
iant hR55vMPR still contains this region, it might be possible
that this domain plays a role in the activation of p38 MAPK.
In CAT-R55i-expressing cells, p38 MAPK is activated after
3^3.5 h of IFN-K treatment, the time needed for the produc-
tion of the fusion protein (Fig. 2B). However, with the CAT-
R55i-L351A construct, which does contain an active NLD,
but has a de¢cient DD, it is no longer possible to activate
p38 MAPK (Fig. 2B). This proves that activation of p38
MAPK is solely mediated by a functional DD, without a
contribution of the NLD. As a control, TNF treatment of
the same cells is included, showing that the p38 MAPK path-
way in these cells is intact. Together, our data clearly demon-
strate that hTNF-R55 is su⁄cient to trigger p38 MAPK acti-
vation and that this activation is the result of clustering of an
active form of the DD.
3.3. p42/p44 MAPK activation is mediated by the TNF-R55
death domain
Parallel studies were performed to assess the involvement of
TNF-R55 in the activation of p42/p44 MAPK. Previously, it
was demonstrated that TNF activates p42/p44 MAPK in
L929sA cells [17]. However, the receptor type involved and
the exact signaling pathways are unknown so far. Fig. 3 dem-
onstrates that TNF triggering of hR55wt-expressing cells in-
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Fig. 1. A: Schematic representation of the di¡erent hTNF-R55 proteins. hR55wt: wild-type hTNF-R55; hR55vMPR: hTNF-R55 lacking the
membrane proximal region; CAT-R55i: fusion protein between CAT and the intracellular domain of TNF-R55; CAT-R55i-L351A: CAT-R55i
where Leu-351CAla; CATlinkDD: fusion protein between CAT and TNF-R55-DD with a 15-amino acid linker (Gly4Ser)3 between the two
polypeptides. EC: Extracellular domain; TM: transmembrane domain; MPR: membrane-proximal region; DD: death domain; CAT: chloram-
phenicol acetyltransferase. B: Expression of the CAT-R55i-L351A fusion protein in L929sA cells by inductions with IFN-K. L929sA-CAT-
R55i-L351A cells were either not treated (NI) or treated with IFN-K (1000 IU/ml) for di¡erent time periods. Extracts were made and used in
an enzymatic CAT assay [26].
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deed activates p42/p44 MAPK, as demonstrated via phospho-
speci¢c p42/p44 MAPK antibodies. This activation can be
reproduced by treatment of the same cells with the hTNF-
R55-speci¢c TNF-mutein R32WS86T, showing the involve-
ment of the TNF-R55 in MAPK activation. We could not
longer make use of the agonistic antibody htr1 to trigger
the human receptors, due to activation of p42/p44 MAPK
by the htr1 solution in the parental mouse L929sA cells in
the absence of human receptors (data not shown). Probably
remaining serum proteins in the htr1 preparation are respon-
sible for this activation. Treatment of hR55vMPR-expressing
cells with TNF or R32WS86T also results in p42/p44 MAPK
activation. In order to explore a possible involvement of the
N-spinghomyelinase pathway, expression of CAT-R55i, CAT-
R55i-L351A or CATlinkDD was induced by treatment of the
relevant cells with IFN-K. In both CAT-R55i- and CAT-
linkDD-expressing cell lines this treatment resulted in a clear
activation of p42/p44 MAPK, which could be abolished by
the speci¢c inhibitor PD98059 (Fig. 4). However, the mutant
coding for an inactive DD lacked any ability to activate
MAPK. This demonstrates that, besides activation of the
p38 MAPK activation, TNF-R55-DD can also stimulate
this second class of MAPK, without the need for N-spingho-
myelinase activation.
4. Discussion
MAPK are, among the recently discovered kinases, almost
the most complex ones with multiple and diversi¢ed signaling
functions. External cellular stresses, such as ultraviolet irradi-
ation, chemical heat, osmotic shock, inhibitors of protein syn-
thesis and bacterial lipopolysaccharide, are all able to activate
the stress p38 MAPK and JNK. In addition, the pro-in£am-
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Fig. 3. p42/p44 MAPK activation assay. Parental L929sA cells,
L929sA-hR55wt and L929sA-hR55vMPR cells were serum-starved
as described, followed by treatment of the cells with TNF (2000 IU/
ml) or R32WS86T (10 ng/ml) for 10 or 15 min. Cell lysates were
made and activated p42/p44 MAPK was detected using a phospho-
speci¢c p42/p44 (Thr-202/Tyr-204) MAPK antibody. Equal loading
was con¢rmed by anti-p38 MAPK antibody (data not shown).
Fig. 2. p38 MAPK activation assay. Activation of p38 MAPK was assayed with a phospho-speci¢c p38 (Thr-180/Tyr-182) MAPK antibody.
Equal loading was con¢rmed by anti-p38 MAPK antibody (data not shown). A: L929sA-hR55wt and L929sA-hR55vMPR cells were either
not treated (NI), or treated with TNF (2000 IU/ml) or htr1 (100 ng/ml) for 5 or 15 min. B: L929sA-CAT-R55i and L929sA-CAT-R55i-L351A
cells were not treated (NI), treated with TNF (2000 IU/ml) as a control or treated with IFN-K (1000 IU/ml) for various times to induce expres-
sion of the CAT fusion products.
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matory cytokines IL-1 and TNF were shown to be strong
inducers of these kinases. Furthermore, the so-called mitogen
p42/p44 MAPK do also play a prominent role in the pleio-
tropic action of TNF and IL-1.
In this paper we show that TNF strongly activates p38
MAPK as well as p42/p44 MAPK through hTNF-R55. More-
over, we clearly demonstrate that their activation is triggered
by clustering of a functional TNF-R55-DD.
Both the p55 and p75 TNF receptor have been shown to
activate JNK via aggregation of the adaptor molecule TRAF2
[11,29]. Also the activation of p38 MAPK after TNF stimu-
lation was reported to be mediated via TRAF2 [30]. However,
in all of these experiments the involvement of TRAF2 in TNF
signaling was demonstrated by overexpression of the domi-
nant negative variant of TRAF2 which was able to block
TNF-R55 and TNF-R75-mediated JNK and p38 MAPK ac-
tivation. As mentioned in the introduction, only JNK activa-
tion, and not NF-UB translocation, by TNF was indeed ab-
rogated in cells lacking endogenous TRAF2 [27,28].
Therefore, we investigated the role of TNF-R55 and, more
particularly, of its DD, in MAPK activation via a more phys-
iologically relevant system, i.e. by stably expressing the
hTNF-R55 or various recombinant mutants in the mouse ¢-
brosarcoma cell line L929sA. In these cells TNF-R55 seems to
be the sole mediator of p38 MAPK activation by TNF, as
speci¢c triggering of hTNF-R55 activates p38 MAPK as
strongly as TNF itself. Moreover, speci¢c triggering of human
TNF-R75 in TNF-R75-transfected L929sA cells could not
induce phosphorylation of p38 MAPK (E. Boone, unpub-
lished data). Apparently, the reported TNF-R75-mediated
p38 MAPK activation is highly cell-speci¢c [11]. As reported
here, in hTNF-R55 the DD is clearly the crucial domain for
p38 MAPK activation in L929sA cells. However, whether it
activates p38 MAPK solely via TRAF2 in these cells needs
further investigation. As a matter of fact, the lack of TNF-
R75-mediated p38 MAPK activation in L929sA cells argues
that TRAF2 might not be the most important mediator of
TNF-induced p38 MAPK activation. One possible candidate
for an alternative p38 MAPK signaling pathway is the TNF-
R55-associated protein MADD [31], which has been shown to
activate not only JNK and p42/p44 MAPK but also p38
MAPK (personal communication of Drs. A. Goldfeld and
B. Brinkman, Dana-Farber Cancer Institute and Harvard
Medical School, Boston, MA, USA).
Growth factor-mediated activation of p42/p44 MAPK oc-
curs by activation of the Ras-Raf-1 pathway. TNF signaling
via Raf-1 is, however, still controversial in that in some sys-
tems TNF e¡ects are Raf-1 dependent [36] and in others
clearly Raf-1 independent [13,15,37]. Activation of Raf-1 by
TNF is assumed to be generated through activation of N-
spinghomyelinase and recruitment of Raf-1 by Ras to the
membrane [20,36]. However, Muºller and coworkers recently
published that the observed TNF-induced Ras-Raf-1 binding
does not lead to the subsequent activation of Raf-1 kinase
[25]. Correspondingly, TNF-induced p42/p44 MAPK activity
was shown to be Raf-1 independent in macrophages [15].
Moreover, the involvement of Raf-1 in some cell lines was
only suggested by mimicking the TNF signaling pathway
with exogenously added ceramide or sphingomyelinase-C
[38]. In this respect we now communicate that the mem-
brane-proximal region required for activation of Raf-1 is
not involved in TNF-R55-mediated activation of p42/p44
MAPK and that the DD is necessary and su⁄cient. These
data counteract the generally assumed idea that activation
of p42/p44 MAPK by TNF would be mediated by Raf-1.
Again, the recently cloned MADD protein could be the true
mediator of TNF signaling to p42/p44 MAPK. Future experi-
ments with MADD knockout mice will establish the exact
involvement of MADD in p42/p44 and p38 MAPK activa-
tion.
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